Related Experiment Videos
[Immunotherapy for unresectable pancreatic cancer]
1Dept. of Digestive Surgery and Surgical Oncology (Surgery II), Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 28, 2002
Summary
Cell therapies, including cytotoxic T lymphocytes (CTLs) and MUC1-peptide pulsed dendritic cells, show promise for treating unresectable pancreatic cancer. Cancer peptide vaccine therapy is also under investigation.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Context:
- Pancreatic cancer remains a significant challenge, particularly when unresectable.
- Existing treatments have limitations, necessitating novel therapeutic strategies.
Purpose:
- To evaluate the efficacy of various cell-based immunotherapies and peptide vaccines for unresectable pancreatic cancer.
- To explore the potential of lymphokine-activated killer cells, cytotoxic T lymphocytes (CTLs), and MUC1-targeted therapies.
Summary:
- Cell therapies were investigated, including CTLs generated via mixed lymphocyte culture (MLC) with autologous tumor cells and MUC1-recognizing CTLs.
- Therapy using MUC1 peptide-pulsed dendritic cells (MUC1-DCs) and MUC1-CTLs was also performed.
- Cancer peptide vaccine therapy trials are ongoing for unresectable pancreatic cancer.
Impact:
- CTL therapy demonstrated effectiveness in some patients with unresectable pancreatic cancer.
- MUC1-targeted cell therapy showed efficacy in one out of three cases.
- Cell therapy and peptide vaccine therapy represent promising future directions for pancreatic cancer treatment.